AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis
Portfolio Pulse from Vandana Singh
AbbVie's drug Skyrizi has shown superiority over Amgen's Otezla in a head-to-head Phase 4 study for moderate plaque psoriasis. The study achieved all primary and ranked secondary endpoints without identifying new safety signals. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
July 26, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amgen's Otezla has shown inferior results compared to AbbVie's Skyrizi in a Phase 4 study, which could negatively impact its market position and stock value.
The inferior performance of Otezla compared to Skyrizi in the Phase 4 study could negatively impact Amgen's market position in the treatment of moderate plaque psoriasis. This could potentially lead to decreased sales and a negative impact on the company's stock value.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
AbbVie's Skyrizi has shown positive results in a Phase 4 study, potentially boosting its market position and stock value.
The positive results from the Phase 4 study of Skyrizi could strengthen AbbVie's market position in the treatment of moderate plaque psoriasis. This could potentially lead to increased sales and a positive impact on the company's stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100